Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Core Insights - Abivax will host a Key Opinion Leader (KOL) webcast on March 17, 2025, featuring Dr. David Rubin discussing the treatment landscape for ulcerative colitis and the ABTECT Phase 3 trial of obefazimod [1][2] Event Details - The webcast is scheduled for March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET) and will be conducted virtually [4] - Registration for the event can be completed through a provided link [4] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases, with its lead drug candidate obefazimod (ABX464) currently in Phase 3 trials for ulcerative colitis [5]